AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8934059 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic OC pill containing 35 mg ethinyl estradiol (EE) and 50 mg desogestrel (DSG) in the first seven tablets; 30 mg EE and 100 mg DSG in tablets 8 to 14, and 30 mg EE and 150 mg DSG in tablets 15 to 21
Number of subjects: 51
Study 8934059 — intervention group
Group type: EXPERIMENTAL
Intervention: OC pills containing 20 mg EE plus 150 mg DSG (15 patients) or 75 mg of gestodene (14 patients)
Number of subjects: 51
Study 1913714 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.2 mg/kg)
Number of subjects: 10
Study 1913714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6358486 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological techniques for reducing dependence on hypnotics
Number of subjects: 0
Study 6358486 — intervention group
Group type: COMPARATOR
Intervention: Control group (users who did not receive psychological treatment)
Number of subjects: 0
Study 29373687 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 213
Study 29373687 — intervention group
Group type: COMPARATOR
Intervention: Stavudine
Number of subjects: 213
Study 26497446 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit negative associations
Number of subjects: 63
Study 26497446 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit spider fear
Number of subjects: 63
Study 26497446 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit avoidance tendencies
Number of subjects: 63
Study 26497446 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory capacity (WMC)
Number of subjects: 63
Study 25383780 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct access to low-dose computed tomography (LDCT) combined with a Continuing Medical Education (CME) meeting on lung cancer diagnosis
Number of subjects: 648
Study 25383780 — intervention group
Group type: EXPERIMENTAL
Intervention: CME participation
Number of subjects: 648
Study 25383780 — intervention group
Group type: COMPARATOR
Intervention: Usual fast-track evaluation
Number of subjects: 648
Study 21967845 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-DHA (400 mg/d)
Number of subjects: 2911
Study 21967845 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA (2 g/d)
Number of subjects: 2911
Study 21967845 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EPA-DHA and ALA
Number of subjects: 2911
Study 21967845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2911
Study 21967845 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-DHA
Number of subjects: 2911
Study 21967845 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA
Number of subjects: 2911
Study 21309493 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg orally 1 hour prior to HSG
Number of subjects: 60
Study 21309493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17681958 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa weight-based dosing (0.75 mcg/kg every 2 weeks for 26 weeks)
Number of subjects: 165
Study 17681958 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa fixed dosing (50 mcg every 2 weeks for 26 weeks)
Number of subjects: 165
Study 17681958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 16572737 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency oscillatory ventilation (HFOV)
Number of subjects: 16
Study 16572737 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (control)
Number of subjects: 16
Study 16572737 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma sICAM-1 levels
Number of subjects: 16
Study 16572737 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma sICAM-1 on day 3
Number of subjects: 16
Study 16572737 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 16
Study 12167135 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine (mean dose 18 mg, titrated to maximum 24 mg over 4 weeks)
Number of subjects: 200
Study 12167135 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 200
Study 10210050 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 0.5 mg x kg(‐1)
Number of subjects: 36
Study 10210050 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 0.25 mg x kg(‐1)
Number of subjects: 36
Study 10210050 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 0.05 ml x kg(‐1)
Number of subjects: 36
Study 8590121 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cold therapy (cold therapy pads placed over a thin dressing, maintained at 42 degrees F for the immediate postoperative period, used for an average of 3 days)
Number of subjects: 52
Study 8590121 — intervention group
Group type: COMPARATOR
Intervention: Control group (identical operative and postoperative procedure without continuous cold therapy)
Number of subjects: 52
Study 2709943 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 therapy
Number of subjects: 51
Study 2709943 — intervention group
Group type: COMPARATOR
Intervention: No prostaglandin E1 therapy (Control)
Number of subjects: 51
Study 61854 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG operant conditioning
Number of subjects: 5
Study 61854 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp EMG suppression reinforcement
Number of subjects: 5
Study 61854 — intervention group
Group type: COMPARATOR
Intervention: Control periods
Number of subjects: 5
Study 31036412 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan (3 g/d for 12 weeks)
Number of subjects: 96
Study 31036412 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 3 g/d for 12 weeks)
Number of subjects: 96
Study 27489077 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet-based cognitive behavioral therapy (ICBT) for 9 weeks
Number of subjects: 50
Study 27489077 — intervention group
Group type: COMPARATOR
Intervention: Web-based moderated discussion forum (DF)
Number of subjects: 50
Study 27489077 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet-based cognitive behavioral therapy (ICBT)
Number of subjects: 50
Study 25097243 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL (Intraocular Lens)
Number of subjects: 103
Study 25097243 — intervention group
Group type: COMPARATOR
Intervention: Contact Lens (CL)
Number of subjects: 103
Study 25097243 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IOL and CL groups
Number of subjects: 103
Study 23786339 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oxytocin (4 mU/min, increasing every 30 minutes to 64 mU/min)
Number of subjects: 94
Study 23786339 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose oxytocin (2 mU/min, increasing every 30 minutes to 32 mU/min)
Number of subjects: 94
Study 23786339 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oxytocin
Number of subjects: 94
Study 23786339 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose oxytocin
Number of subjects: 94
Study 19914604 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA (300 mg)
Number of subjects: 200
Study 19914604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 18381306 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic Bankart repair
Number of subjects: 88
Study 16323004 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular vision
Number of subjects: 0
Study 16323004 — intervention group
Group type: COMPARATOR
Intervention: Monocular viewing (one eye occluded)
Number of subjects: 0
Study 12727080 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 4.5 g total for 3 weeks (1 x 500 mg weekly for 3 days)
Number of subjects: 89
Study 12727080 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg b.i.d. for 20 days
Number of subjects: 89
Study 10811587 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-irradiation (192Ir)
Number of subjects: 38
Study 10811587 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dummy seeds)
Number of subjects: 38
Study 9387566 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinamide (20mg/kg orally every day for eight weeks)
Number of subjects: 80
Study 9387566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 7876035 — intervention group
Group type: EXPERIMENTAL
Intervention: Deceptive questions (D)
Number of subjects: 32
Study 7876035 — intervention group
Group type: COMPARATOR
Intervention: Honest questions (H)
Number of subjects: 32
Study 7876035 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-choice condition
Number of subjects: 32
Study 7876035 — intervention group
Group type: COMPARATOR
Intervention: No-choice condition
Number of subjects: 32
Study 3411756 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-session risk-reduction intervention
Number of subjects: 1447
Study 31479006 — intervention group
Group type: EXPERIMENTAL
Intervention: High amount high intensity treadmill exercise (HAHI)
Number of subjects: 103
Study 31479006 — intervention group
Group type: EXPERIMENTAL
Intervention: High amount low intensity treadmill exercise (HALI)
Number of subjects: 103
Study 31479006 — intervention group
Group type: EXPERIMENTAL
Intervention: Low amount low intensity treadmill exercise
Number of subjects: 103
Study 31479006 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 103
Study 31479006 — intervention group
Group type: EXPERIMENTAL
Intervention: All exercise groups
Number of subjects: 103
Study 31072359 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyriproxyfen (PPF) dissemination devices (0.2-0.3 g PPF in clay pots)
Number of subjects: 20
Study 31072359 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated chamber)
Number of subjects: 20
Study 28122690 — intervention group
Group type: EXPERIMENTAL
Intervention: BATHE interview technique
Number of subjects: 112
Study 28122690 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 112
Study 26885511 — intervention group
Group type: EXPERIMENTAL
Intervention: Toyra(®) virtual reality system combined with conventional therapy
Number of subjects: 31
Study 26885511 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 31
Study 26885511 — intervention group
Group type: EXPERIMENTAL
Intervention: Toyra(®) virtual reality system
Number of subjects: 31
Study 23001079 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation at sensory threshold (ST)
Number of subjects: 19
Study 23001079 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation at 75% of the ST
Number of subjects: 19
Study 23001079 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation at 50% of the ST
Number of subjects: 19
Study 21095620 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (10 μg/kg s.c. for 5 days)
Number of subjects: 114
Study 21095620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 18636325 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing-based intervention for HIV risk
Number of subjects: 530
Study 18636325 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing-based intervention for HIV and IPV risk
Number of subjects: 530
Study 18636325 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 530
Study 17006874 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil treatment
Number of subjects: 101
Study 15011930 — intervention group
Group type: COMPARATOR
Intervention: Mail group
Number of subjects: 78
Study 15011930 — intervention group
Group type: COMPARATOR
Intervention: Interactive group
Number of subjects: 78
Study 15011930 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 78
Study 11709596 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic primer
Number of subjects: 33
Study 11709596 — intervention group
Group type: COMPARATOR
Intervention: Conventional primer
Number of subjects: 33
Study 8804929 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled lysine-acetylsalicylate (L-ASA) 90 mg.mL-1
Number of subjects: 9
Study 8804929 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (glycine, 30 mg.mL-1)
Number of subjects: 9
Study 1505562 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (100 mg)
Number of subjects: 61
Study 1505562 — intervention group
Group type: EXPERIMENTAL
Intervention: Ajmaline (50 mg)
Number of subjects: 61
Study 6368960 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (CP) subcutaneous on day 14
Number of subjects: 222
Study 6368960 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (CP) intravenous on day 14
Number of subjects: 222
Study 6368960 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (CP) subcutaneous on day 1
Number of subjects: 222
Study 6368960 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (CP) intravenous on day 1
Number of subjects: 222
Study 6368960 — intervention group
Group type: COMPARATOR
Intervention: VAC/FMC chemotherapy
Number of subjects: 222
Study 30698045 — intervention group
Group type: EXPERIMENTAL
Intervention: GP2017 (40 mg subcutaneous injection)
Number of subjects: 0
Study 30698045 — intervention group
Group type: EXPERIMENTAL
Intervention: GP2017 via autoinjector (AI)
Number of subjects: 0
Study 30698045 — intervention group
Group type: COMPARATOR
Intervention: GP2017 (AI and PFS)
Number of subjects: 0
Study 29752620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Body Image and Self-Care (CBT-BISC)
Number of subjects: 44
Study 29752620 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 44
Study 25689042 — intervention group
Group type: EXPERIMENTAL
Intervention: Malabsorption blood test (MBT) with pancreatic enzyme administration
Number of subjects: 0
Study 25689042 — intervention group
Group type: EXPERIMENTAL
Intervention: Malabsorption blood test (MBT) without pancreatic enzyme administration
Number of subjects: 0
Study 25689042 — intervention group
Group type: COMPARATOR
Intervention: Malabsorption blood test (MBT) with enzymes taken 30 minutes after MBT
Number of subjects: 0
Study 25689042 — intervention group
Group type: COMPARATOR
Intervention: Malabsorption blood test (MBT) with enzymes taken 60 minutes after MBT
Number of subjects: 0
Study 23535332 — intervention group
Group type: EXPERIMENTAL
Intervention: RESMENA diet (30% proteins, 30% lipids, 40% carbohydrates, seven-times/day, low glycemic load, high antioxidant capacity, high n-3 fatty acids)
Number of subjects: 79
Study 23535332 — intervention group
Group type: COMPARATOR
Intervention: Control diet based on American Health Association criteria
Number of subjects: 79
Study 22483680 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabiximols (low dose: 1-4 sprays/day)
Number of subjects: 360
Study 22483680 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabiximols (medium dose: 6-10 sprays/day)
Number of subjects: 360
Study 22483680 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabiximols (high dose: 11-16 sprays/day)
Number of subjects: 360
Study 22483680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 19103443 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.6 mg/kg
Number of subjects: 12
Study 19103443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19103443 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 12
Study 17227784 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress echocardiography (SEcho)
Number of subjects: 433
Study 17227784 — intervention group
Group type: COMPARATOR
Intervention: Exercise electrocardiography (ExECG)
Number of subjects: 433
Study 15191866 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal interposition without a pouch (J-I)
Number of subjects: 26
Study 15191866 — intervention group
Group type: COMPARATOR
Intervention: Jejunal interposition with a pouch (J-P)
Number of subjects: 26
Study 11682411 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL mouth-to-mouth ventilation tidal volume
Number of subjects: 20
Study 11682411 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mL mouth-to-mouth ventilation tidal volume
Number of subjects: 20
Study 11682411 — intervention group
Group type: COMPARATOR
Intervention: Room air control (21% oxygen)
Number of subjects: 20
Study 10410576 — intervention group
Group type: EXPERIMENTAL
Intervention: A60-ELISA test with Immune kit
Number of subjects: 213
Study 10410576 — intervention group
Group type: COMPARATOR
Intervention: Tuberculin test using 2 units of tuberculin Rt23
Number of subjects: 213
Study 10410576 — intervention group
Group type: EXPERIMENTAL
Intervention: A60-ELISA test
Number of subjects: 213
Study 9297313 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte‐filtrated blood
Number of subjects: 60
Study 9297313 — intervention group
Group type: COMPARATOR
Intervention: Whole blood transfusion
Number of subjects: 60
Study 2566112 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 600 mg
Number of subjects: 5
Study 2566112 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol 20 mg
Number of subjects: 5
Study 2566112 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg
Number of subjects: 5
Study 2566112 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 30 mg
Number of subjects: 5
Study 2566112 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg
Number of subjects: 5
Study 2566112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 269633 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 46
Study 269633 — intervention group
Group type: COMPARATOR
Intervention: No oxytocin infusion (Control)
Number of subjects: 46
Study 31488492 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zoledronic acid (ZA)
Number of subjects: 0
Study 31488492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28817434 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus + reduced Tacrolimus (EVR + TAC)
Number of subjects: 719
Study 28817434 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus control (TAC)
Number of subjects: 719
Study 28817434 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus elimination (TAC elimination)
Number of subjects: 719
Study 26297361 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 78
Study 26297361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 24144899 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz (EFV) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs)
Number of subjects: 0
Study 24144899 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r) plus 2 NRTIs
Number of subjects: 0
Study 24144899 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r) plus EFV without NRTI
Number of subjects: 0
Study 24144899 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTI selection (ZDV, d4T, TDF)
Number of subjects: 0
Study 24144899 — intervention group
Group type: COMPARATOR
Intervention: LPV/r
Number of subjects: 0
Study 24144899 — intervention group
Group type: COMPARATOR
Intervention: EFV regimens without TDF
Number of subjects: 0
Study 24144899 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0
Study 21594217 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (2 g amoxicillin single preoperative dose)
Number of subjects: 240
Study 21594217 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (single preoperative 2 g amoxicillin followed by 500 mg three times daily for 5 days)
Number of subjects: 240
Study 21594217 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (postoperative amoxicillin with clavulanic acid 625 mg three times daily for 5 days)
Number of subjects: 240
Study 19786634 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS SR (n=131)
Number of subjects: 536
Study 19786634 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS MR (n=135)
Number of subjects: 536
Study 19786634 — intervention group
Group type: COMPARATOR
Intervention: Control (bare-metal stent, n=270)
Number of subjects: 536
Study 16459722 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg every other day (EOD) interferon beta-1b
Number of subjects: 149
Study 16459722 — intervention group
Group type: COMPARATOR
Intervention: 30 microg once weekly (OW) interferon beta-1a
Number of subjects: 149
Study 15684776 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colectomy (LAC)
Number of subjects: 49
Study 15684776 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy (OC)
Number of subjects: 49
Study 15684776 — intervention group
Group type: COMPARATOR
Intervention: Converted to open procedure (COC)
Number of subjects: 49
Study 11526364 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 136
Study 11526364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 9241002 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 900 mg daily
Number of subjects: 0
Study 9241002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8512713 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 11
Study 8512713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2447516 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemophane (HE)
Number of subjects: 10
Study 2447516 — intervention group
Group type: COMPARATOR
Intervention: Cuprophane (CU)
Number of subjects: 10
Study 31620974 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone coaching intervention (n = 12 calls)
Number of subjects: 288
Study 31620974 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving a single written recommendation
Number of subjects: 288
Study 31620974 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone coaching intervention
Number of subjects: 288
Study 29105489 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term CHS (5 days)
Number of subjects: 90
Study 29105489 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term CHS + vitamin C (12 g/100 l drinking water)
Number of subjects: 90
Study 29105489 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-term CHS (10 days)
Number of subjects: 90